Expression of co-stimulatory molecules by tumor cells decreases tumorigenicity but may also reduce systemic antitumor immunity

被引:32
作者
Chong, H
Hutchinson, G
Hart, IR
Vile, RG
机构
[1] ST THOMAS HOSP,RAYNE INST,IMPERIAL CANC RES FUND,LAB CANC GENE THERAPY,LONDON SE1 7EH,ENGLAND
[2] ST THOMAS HOSP,RAYNE INST,ICRF LAB,RICHARD DIMBLEBY DEPT CANC RES,LONDON SE1 7EH,ENGLAND
关键词
D O I
10.1089/hum.1996.7.14-1771
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Many tumor cells do not express co-stimulatory molecules, and this may account, in part, for their poor ability to stimulate T cells directly, One strategy to enhance immune recognition would be to express such molecules on the tumor cell, Here, we show that expression of a member of the B7 family of co-stimulatory molecules by CMT93 murine colorectal tumor or 1735 murine melanoma cells resulted in a local antitumor response in immunocompetent mice, The antitumor effect was diminished in athymic nude mice, indicating that T cells played an important part in this response, The ability of the B7-expressing tumor cells to generate systemic protective immunity was investigated by excision of tumors that developed from the initial inoculation followed by rechallenge with parental tumor cells, CMT93 is a poorly immunogenic tumor and no significant systemic immunity was elicited by the expression of B7-1 in these cells, 1735 melanoma is a mildly immunogenic tumor, Unexpectedly, the systemic immunity obtained with 1735 tumors expressing B7-1 or B7-2 was weaker than that generated by parental 1735 cells (p < 0.001, stratified logrank test), even when coexpression of interferon-gamma in the B7-1 cells produced high levels of surface MHC class I expression, These results suggest that some caution is appropriate when considering the use of these molecules in the gene therapy of cancer.
引用
收藏
页码:1771 / 1779
页数:9
相关论文
共 55 条
  • [1] ALLIONE A, 1994, CANCER RES, V54, P6022
  • [2] Altman DG., 1991, PRACTICAL STAT MED R
  • [3] CD28 INTERACTION WITH B7-COSTIMULATES PRIMARY ALLOGENEIC PROLIFERATIVE RESPONSES AND CYTOTOXICITY MEDIATED BY SMALL, RESTING LYMPHOCYTES-T
    AZUMA, M
    CAYABYAB, M
    BUCK, D
    PHILLIPS, JH
    LANIER, LL
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) : 353 - 360
  • [4] B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28
    AZUMA, M
    ITO, D
    YAGITA, H
    OKUMURA, K
    PHILLIPS, JH
    LANIER, LL
    SOMOZA, C
    [J]. NATURE, 1993, 366 (6450) : 76 - 79
  • [5] MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II(+)B7-1(+) TUMOR-CELLS ARE POTENT VACCINES FOR STIMULATING TUMOR REJECTION IN TUMOR-BEARING MICE
    BASKAR, S
    GLIMCHER, L
    NABAVI, N
    JONES, RT
    OSTRANDROSENBERG, S
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) : 619 - 629
  • [6] NEW PERSPECTIVES OF CD28-B7-MEDIATED T-CELL COSTIMULATION
    BLUESTONE, JA
    [J]. IMMUNITY, 1995, 2 (06) : 555 - 559
  • [7] BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.iy.12.040194.002005
  • [8] TUMOR-CELLS COTRANSFECTED WITH INTERLEUKIN-7 AND B7.1 GENES INDUCE CD25 AND CD28 ON TUMOR-INFILTRATING T-LYMPHOCYTES AND ARE STRONG VACCINES
    CAYEUX, S
    BECK, C
    AICHER, A
    DORKEN, B
    BLANKENSTEIN, T
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (08) : 2325 - 2331
  • [9] TUMOR IMMUNOGENICITY DETERMINES THE EFFECT OF B7 COSTIMULATION ON T-CELL-MEDIATED TUMOR-IMMUNITY
    CHEN, LP
    MCGOWAN, P
    ASHE, S
    JOHNSTON, J
    LI, YW
    HELLSTROM, I
    HELLSTROM, KE
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) : 523 - 532
  • [10] COSTIMULATION OF ANTITUMOR IMMUNITY BY THE B7 COUNTERRECEPTOR FOR THE LYMPHOCYTE-T MOLECULES CD28 AND CTLA-4
    CHEN, LP
    ASHE, S
    BRADY, WA
    HELLSTROM, I
    HELLSTROM, KE
    LEDBETTER, JA
    MCGOWAN, P
    LINSLEY, PS
    [J]. CELL, 1992, 71 (07) : 1093 - 1102